CAJ | 학술논문

目的：探讨孟鲁司特钠配合常规治疗对儿童过敏性紫癜的临床疗效。方法选取2012年12月至2013年12月秦皇岛市第二医院收治的过敏性紫癜患儿64例，采用随机数字表法分为试验组和对照组，每组32例。对照组给予氯雷他定颗粒口服，5 mg／d，西咪替丁注射液20 mg／（ kg? d），每日2次肌内注射，试验组在对照组的基础上加服孟鲁司特钠片4 mg／d。治疗1个月后分别对比观察两组患者临床疗效及尿生化指标，并随访1年对比复发率。结果治疗后，试验组总有效率为93.8％，对照组为84.4％，两组临床疗效比较差异有统计学意义（ P＜0.05）；治疗后试验组微量白蛋白、β2微球蛋白均显著低于对照组[（11±5） mg／L 比（35±9） mg／L，（0.39±0.06） mg／L 比（0.57±0.07） mg／L]，差异有统计意义（P＜0.05）；试验组复发率显著低于对照组[12.5％（4／32）比31.3％（10／32），P＜0.05]。结论孟鲁司特钠可有效治疗小儿过敏性紫癜，临床效果显著，并可有效降低此病复发率。
목적：탐토맹로사특납배합상규치료대인동과민성자전적림상료효。방법선취2012년12월지2013년12월진황도시제이의원수치적과민성자전환인64례，채용수궤수자표법분위시험조화대조조，매조32례。대조조급여록뢰타정과립구복，5 mg／d，서미체정주사액20 mg／（ kg? d），매일2차기내주사，시험조재대조조적기출상가복맹로사특납편4 mg／d。치료1개월후분별대비관찰량조환자림상료효급뇨생화지표，병수방1년대비복발솔。결과치료후，시험조총유효솔위93.8％，대조조위84.4％，량조림상료효비교차이유통계학의의（ P＜0.05）；치료후시험조미량백단백、β2미구단백균현저저우대조조[（11±5） mg／L 비（35±9） mg／L，（0.39±0.06） mg／L 비（0.57±0.07） mg／L]，차이유통계의의（P＜0.05）；시험조복발솔현저저우대조조[12.5％（4／32）비31.3％（10／32），P＜0.05]。결론맹로사특납가유효치료소인과민성자전，림상효과현저，병가유효강저차병복발솔。
Objective To explore clinical curative effect of the montelukast sodium with conventional treatment for allergic purpura in children.Methods A total of 64 children of allergic purpura were chosen in Qinghuangdao City Second Hospital from Dec.2012 to Dec.2013, according to the random number table method,they were divided into trial group and control group,32 cases in each group.The control group was given oral loratadine particles 5 mg/d,and cimetidine injection intramuscular injection 20 mg/( kg? d) ,two times a day;the trial group was added service montelukast sodium tablets 4 mg/d on the basis of the control group′s therapy.Clinical efficacy were observed and urinary biochemical indices of the two groups were com-pared after a month of treatment,and follow-up was done for one year and the recurrence rate was observed and compared.Results After treatment,total effectiveness was 93.8% in the trial group,84.4% in the control group,the difference was statistically significant (P<0.05);the micro albumin andβ2 microglobulin in the trial group after treatment were significantly lower than the control group[(11 ±5) mg/L vs (35 ± 9) mg/L,(0.39 ±0.06) mg/L vs (0.57 ±0.07) mg/L],the difference was statistically significant (P<0.05);the recurrence rate in the trial group(12.5%)(4/32) was significantly lower than that in the control group(31.2%)(10/32)(P<0.05).Conclusion Montelukast is effective in treating allergic purpura in children,with significant clinical effect,which can effectively reduce recurrence rate of the disease.